Tafasitamab and Lenalidomide after CAR-T for Large B-cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) or related subtypes.
- You must be 18 years or older.
- You must have had CAR-T therapy (with the drug axicabtagene-ciloleucel) and still have some disease seen on a PET/CT scan done 21 to 60 days after that treatment.
- You must be well enough to be up and about at least half of the day (ECOG performance status 0-2).
- You must have adequate liver, kidney, and bone marrow function, as shown by blood tests.
- Women who can become pregnant must use two reliable forms of birth control starting 4 weeks before treatment and continuing until 4 weeks after it ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This study tests a new combination of medicines, chosen based on your tumor's specific features, for people whose lymphoma did not respond to CD19 CAR-T therapy. The goal is to find a more effective treatment option for this difficult situation.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.